It is made available under a CC-BY-NC-ND 4.0 International license .

1 Method versatility in RNA extraction-free PCR detection of SARS-CoV-2 in

2 saliva samples

- 3
- 4 Orchid M. Allicock^{1†}, Devyn Yolda-Carr¹, Rebecca Earnest¹, Mallery I. Breban¹, Noel Vega¹,
- 5 Isabel M. Ott¹, Chaney Kalinich¹, Tara Alpert¹, Mary E. Petrone¹, Anne L. Wyllie¹
- 6
- 7 Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New
- 8 Haven, CT 06510, USA
- 9
- 10 ⁺Correspondence: Orchid M. Allicock
- 11 60 College Street, New Haven, CT 06510
- 12 Phone: +1 (201) 401-4573
- 13 Fax: +1 (203) 785-7356
- 14 E-mail: <u>orchid.allicock@yale.edu</u>
- 15 Original Article
- 16
- 17 Keywords: SARS-CoV-2, COVID-19, heat inactivation, testing

18

- 19
- 20

It is made available under a CC-BY-NC-ND 4.0 International license .

21 Abstract

Early in the pandemic, a simple, open-source, RNA extraction-free RT-gPCR protocol for 22 23 SARS-CoV-2 detection in saliva was developed and made widely available. This simplified approach (SalivaDirect) requires only sample treatment with proteinase K prior 24 25 to PCR testing. However, feedback from clinical laboratories highlighted a need for a flexible workflow that can be seamlessly integrated into their current health and safety 26 requirements for the receiving and handling of potentially infectious samples. To address 27 28 these varying needs, we explored additional pre-PCR workflows. We built upon the original SalivaDirect workflow to include an initial incubation step (95°C for 30 minutes, 29 95°C for 5 minutes or 65°C for 15 minutes) with or without addition of proteinase K. The 30 31 limit of detection for the workflows tested did not significantly differ from that of the original SalivaDirect workflow. When tested on de-identified saliva samples from confirmed 32 33 COVID-19 individuals, these workflows also produced comparable virus detection and 34 assay sensitivities, as determined by RT-qPCR analysis. Exclusion of proteinase K did not negatively affect the sensitivity of the assay. The addition of multiple heat 35 pretreatment options to the SalivaDirect protocol increases the accessibility of this cost-36 effective SARS-CoV-2 test as it gives diagnostic laboratories the flexibility to implement 37 the workflow which best suits their safety protocols. 38

It is made available under a CC-BY-NC-ND 4.0 International license .

39 Introduction

Almost two years after the emergence of SARS-CoV-2, diagnostic testing remains an 40 important mitigation strategy. As outbreaks and testing policies evolve and as screening 41 testing has emerged as a key feature enabling communities to safely re-open, labs have 42 had to adapt to the changing needs of their local communities. Throughout, this has often 43 required the rapid implementation of alternative or even novel strategies to meet testing 44 45 demands. However efforts have been hampered with staffing shortages, supply chain 46 disruptions and slow regulatory approval for alternative test protocols or testing instrumentation. Combined, these challenges highlight a great need for alternative testing 47 strategies that a) utilize locally available and inexpensive testing materials, and b) are 48 49 easy to adopt in either existing or newly created COVID-19 testing laboratories.

50

Alternative testing strategies should fit seamlessly into an existing workflow of a 51 52 laboratory, while adhering to relevant biosafety and biosecurity requirements. Within the 53 limits imposed by the mandatory Laboratory Biosafety Guidelines for Handling and 54 Processing Specimens issued by governing bodies¹, each laboratory has their own 55 protocols when it comes to the intake and processing of infectious agents. As such, adopting additional protocols to help meet mass testing needs, with limited or no flexibility 56 in the reagents, kits or instrumentation permitted for use, can result in delayed test 57 implementation due to the additional investment required or supply chain disruptions. 58

59

In an effort to increase access to COVID-19 testing by minimizing test implementation
challenges, we developed a freely available, open-source saliva-based RT-qPCR

medRxiv preprint doi: https://doi.org/10.1101/2021.12.27.21268334; this version posted December 30, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

diagnostic assay (SalivaDirect) with a simplified and flexible workflow. Key to this approach was obviating the need for sample collection by trained healthcare personnel, removing the requirement for specific collection devices and transport media, while validating reagents and instrumentation from multiple suppliers to enable laboratories to utilize their existing infrastructure, or when needed, to help circumvent supply chain disruptions.

68

However, as SalivaDirect was made available to laboratories around the US, the diversity 69 in specimen handling processing requirements when working with potentially infectious 70 71 samples containing this novel coronavirus limited implementation in some sites. Upon 72 receipt of clinical samples, laboratories employ different strategies for viral inactivation before processing including the addition of solvent/detergents, low pH inactivation, 73 irradiation, or heat ^{2, 3}. Previous studies have demonstrated that heat alone is capable of 74 effective viral inactivation of SARS⁴ and Middle East Respiratory Syndrome^{5, 6}, and more 75 recently, also for SARS-CoV-2^{2, 7, 8}. Given the affordability and broad availability of 76 heating sources in clinical laboratories (e.g. heating block/water bath), we sought to 77 explore additional workflows which incorporate heat-pretreatment to permit safer sample 78 handling. Using spiked and clinical saliva samples, we evaluated the effect of thermal 79 incubation of samples on the sensitivity of SARS-CoV-2 detection prior to testing in the 80 SalivaDirect assay. 81

82

83 oMaterials and Methods

84 Ethics statement and sample collection

It is made available under a CC-BY-NC-ND 4.0 International license .

85 For the spiking experiments, the use of de-identified specimens from healthy or SARS-CoV-2-positive individuals was approved by the Institutional Review Board of the Yale 86 87 Human Research Protection Program (FWA00002571, Protocol ID. 2000027690) ⁹. For the clinical evaluation of the workflows, de-identified saliva samples were collected using 88 previously developed saliva self-collection protocols ¹⁰, and was approved by the 89 90 Institutional Review Board of the Yale Human Research Protection Program (Protocol ID. 2000029876). For both studies, participants were informed in writing about the purpose 91 and procedure of the study, and consented to study participation through the act of 92 providing the saliva sample. All samples were transferred at room temperature to the 93 laboratory, and stored within 12 hours at -80°C until further analysis. 94

95

96 Alternate workflows

Saliva samples were thawed on ice and processed using the seven workflows detailed in 97 98 Figure 1. Each of the six new workflows (Figures 1B and 1C) was compared with the original SalivaDirect protocol (Figure 1A). Each sample was first incubated at each of the 99 three different heat pretreatment conditions (65°C for 15 minutes, 95°C for 5 minutes and 100 101 95°C for 30 minutes) using a heating block or a thermocycler. After incubation the samples were split into 2 aliquots; 10 µL was stored at 4°C until testing in RT-qPCR, and 102 50 µL was placed in a separate tube with 2.5 µL (50mg/mL) proteinase K (Thermo Fisher). 103 After vortexing for 1 minute, the samples were incubated at 95°C for 5 minutes to 104 105 inactivate the proteinase K. Following sample processing, 5 µL of the saliva lysates (either 106 stored at 4°C or treated with proteinase K) were tested using the SalivaDirect real-time RT-gPCR assay ¹¹. This assay uses primers and probes from the US CDC, targeting the 107

It is made available under a CC-BY-NC-ND 4.0 International license .

nucleocapsid gene (N1 2019-nCoV_N1) and the human RNase P (RP) as an extraction
control ¹². The RT-qPCR was performed using the Luna Universal Probe One-Step RTqPCR Kit (New England Biolabs) on the BioRad CFX96 Touch (BioRad, CA). A synthetic
SARS-CoV-2 RNA control from Twist Bioscience (San Francisco, CA) was diluted to 100
copies/µL and used as the positive control for N1.

113

114 Limit of detection

115 We performed a limit of detection confirmation study to evaluate the sensitivity of SARS-116 CoV-2 detection when testing samples with a heat-pretreatment step. Samples were 117 prepared by spiking SARS-CoV-2-positive saliva from a healthcare worker diagnosed 118 with COVID-19 with a known virus concentration $(3.7 \times 10^4 \text{ copies/}\mu\text{L})$ into saliva samples 119 from healthy individuals (negative for SARS-CoV-2 RNA). Spiked saliva samples at 120 concentrations of 50, 25 and 12 copies/µL were tested in triplicate, and concentrations of 121 6, 3, and 1.5 copies/µL were tested with 20 individual replicates. All samples were tested using the seven workflows depicted in **Figure 1**. The limit of detection for each workflow 122 was determined to be the lowest concentration at which at least 19/20 replicates were 123 positive for SARS-CoV-2 (cycle threshold (Ct) value <40.0). 124

125

126 Workflow validation with SARS-CoV-2 clinical specimens

127 We validated each of the different workflows using 20 de-identified clinical saliva 128 specimens which previously tested positive for SARS-CoV-2 using the standard 129 SalivaDirect workflow (Figure 1A). Each sample was processed by each of the six

It is made available under a CC-BY-NC-ND 4.0 International license .

workflows, and resulting Ct values were compared to those obtained when originallytested by the standard SalivaDirect protocol.

132

133 Data analysis

134 The sensitivity of the different workflows were compared using repeated-measures 135 ANOVA on the Ct values of each replicate or isolate for each workflow, followed by a Tukey post-hoc test to compare individual pairs of conditions. The agreement of Ct values 136 between each of the alternate workflows and original SalivaDirect protocol were assessed 137 using Pearson correlation coefficient. To compare the Ct value in the clinical samples a 138 139 Wilcoxon signed-rank test was performed. The negative RT-gPCR of the target gene was set at the Ct value of 40 for the statistical analysis. A p value < 0.05 was considered 140 statistically significant. All analyses were conducted with GraphPad Prism 9.1.2 141 (GraphPad Software, Inc., San Diego, CA). 142

143

144 **Results**

145 Limit of detection

The limit of detection (LOD) for the original SalivaDirect protocol (reagents and PCR instrument, depending) is as few as 1.5 copies/ μ L ¹³, with the formal LOD recorded at 12 copies/ μ L, reflecting the least sensitive combination of recommended reagents and instruments ¹¹. To determine the LOD of the alternate workflows, we tested spiked saliva samples at 50, 25 and 12 virus RNA copies/ μ L in triplicate, all of which were detected by RT-qPCR (**Table S1**). We confirmed the LOD for each workflow by testing 20 replicates of spiked saliva samples at lower viral copies (6, 3 and 1.5 virus RNA copies/ μ L). While

It is made available under a CC-BY-NC-ND 4.0 International license .

all 20 of the individual replicates of the spiked samples at 6 virus RNA copies/µL tested
positive for each workflow (Figure 2, Table 1), some workflows were more sensitive, with
workflows including a heat incubation step of 65°C for 15 minutes without proteinase K,
and 95°C for 5 minutes with or without proteinase K having a limit of detection of 3 virus
RNA copies/µL.

158

159 Clinical evaluation of heat treatment workflows

To investigate the agreement between each of the different workflows and the original 160 SalivaDirect protocol, 20 saliva samples which previously tested positive for SARS-CoV-161 2 by SalivaDirect (Ct value range 22.16 - 38.71) were processed using each of the 162 different workflows. There was a median Ct difference in workflows of 0.92 to 6.08 across 163 each of the clinical samples (Figure 3A). Ct values from the N1 gene obtained from the 164 original saliva direct workflow correlated with each of the alternate workflows (Pearson r 165 166 > 0.9, p < 0.0001) (Figure S1, Table S2). The workflow that was significantly less efficient at detecting N1 gene than the original was 95°C for 30 minutes with the added proteinase 167 K step (Δ Ct = 1.46, p < 0.001). 168

169

We also investigated the impact of proteinase K on the sensitivity of each workflow (**Figure 3B**). While the addition of proteinase K made no difference when the samples were first incubated at 95°C for 5 minutes, the addition of proteinase K following incubation at 65°C for 15 minutes resulted in an increase in sensitivity (median difference in Ct value = -0.53, p = 0.027). When the proteinase K was added following incubation at

It is made available under a CC-BY-NC-ND 4.0 International license .

175 95°C for 30 minutes however, there was a decrease in sensitivity (median difference in 176 Ct value = 0.79, p = 0.009).

177

The use of the human *RNase P* (RP) control gene in the dualplex PCR helps to monitor for any major degradation or inhibitors in samples. Ct values for RP were significantly higher (indicating reduced detection) for all workflows except when the samples were processed with incubation steps of 65°C for 15 minutes with PK, and 95°C for 5 minutes with PK. None of the saliva samples had Ct values for RP over 35, the threshold for an invalid sample (**Table S2**), demonstrating that none of the workflows negatively affected the quality of the clinical samples.

185

186 Discussion

Saliva as a specimen type is underutilized in molecular diagnostics. Prior to 2020, almost 187 188 all molecular-based diagnostic tests for respiratory infections required nasopharyngeal specimens (e.g aspirate or swabs) with only one test using saliva swabs for the detection 189 of cytomegalovirus ¹⁴. So following the first reports outlining the potential of saliva as a 190 reliable sample type for SARS-CoV-2 detection ^{9, 15, 16} and a means to overcome the 191 numerous challenges that labs were facing with nasopharyngeal swabs, diagnostic and 192 193 research laboratories alike scrambled to devise guidelines and protocols for the safe handling, processing and storage of potentially infectious saliva specimens. Heating 194 samples on arrival for virus inactivation presents a straightforward approach which can 195 196 be easily adapted in a range of laboratory settings. As an additional benefit, heating of samples decreases the viscosity of saliva samples ¹⁷, making sample pipetting easier. 197

It is made available under a CC-BY-NC-ND 4.0 International license .

198

199 In the current study we investigated the addition of thermal incubation prior to testing 200 saliva samples with the simplified RT-qPCR assay, SalivaDirect, and evaluated the effect of heat pre-treatment on the sensitivity of SARS-CoV-2 detection. Although 56°C is 201 commonly used for inactivation of enveloped viruses ¹⁸, higher temperatures have been 202 used for other coronaviruses ⁶. More recently, it has been shown that SARS-CoV-2 viral 203 particles can be inactivated by incubating a sample at 65°C for 15 minutes and 95°C for 204 5 minutes before processing^{7, 8, 19}, without loss of sensitivity in nasopharyngeal swabs 205 206 and sera ^{2,7}. While in the current study, we did not confirm the inactivation of SARS-CoV-207 2 following heat pretreatment, the conditions selected were based on the literature demonstrating the total inactivation of SARS-CoV-2, or, in the case of 95°C for 30 minutes 208 (workflow C), at the request of testing laboratories who were already utilizing this step 209 prior to testing by alternative methods. 210

211

For all workflows investigated, we found a limit of detection of 3 to 6 copies/µL. The 212 robustness of the detection of the N1 gene in saliva has been demonstrated previously. 213 214 with no significant decrease in sensitivity when exposed to moderate heat ^{10, 20}. Additionally, proteinase K also did not significantly affect the overall sensitivity of detection 215 of the N1 gene (paired t test, p = 0.247). Rather, at the lower incubation temperature 216 217 (65°C for 15 minutes), addition of proteinase K marginally increased the sensitivity of detection as compared to samples processed without proteinase K. It is possible that, 218 while 65°C alone can effectively inactivate SARS CoV-2, this is not as effective at 219 "extracting" all of the virus RNA for RT-qPCR detection. Conversely, the addition of the 220

It is made available under a CC-BY-NC-ND 4.0 International license .

proteinase K step to samples incubated at 95°C for 30 minutes significantly decreased 221 222 the sensitivity of both N1 and RNAse P detection when compared to the original 223 SalivaDirect protocol. However, while RP is used as an internal control, the minor differences observed would not affect the outcome of the assay. Proteinase K degrades 224 225 RNases and assists in preserving RNA integrity, hence it is commonly used in the 226 processing of samples for molecular assays, especially in various extraction-free workflows^{21, 22}. Extraction-free workflows with saliva is no exception, and has been 227 incorporated into many saliva-based extraction-free molecular assays ²³⁻²⁶, including 228 229 SalivaDirect.

230

231 The addition of alternate workflows to an already flexible testing framework further support the rapid implementation of the SalivaDirect RT-gPCR assay in diagnostic and 232 233 research laboratories looking to improve access to SARS-CoV-2 testing in their local 234 communities. Importantly, with the addition of pre-treatment heat steps, these expanded workflows help to prevent the exposure of laboratory personnel directly or indirectly 235 236 handling potentially SARS-CoV-2-infected samples, while providing flexibility of 237 adaptation into their existing standard operating procedures. One of the unique attributes of SalivaDirect is it is validated with materials from multiple vendors, to minimize the risk 238 of supply chain issues. The option of omitting proteinase K treatment makes this flexible 239 240 framework even less vulnerable to supply shortages, and more affordable for laboratories - and thus importantly, to their patients. This is especially important for the implementation 241 242 of mass testing strategies in resource-poor areas, or in low-to-middle income countries

It is made available under a CC-BY-NC-ND 4.0 International license .

- 243 which continue to suffer the brunt of the reagent and laboratory consumables shortages
- 244 during the pandemic.
- 245

246 Data Availability

- All of the data generated from this study is in the Supplementary information.
- 248

249 Author contributions

- 250 A.L.W. conceived the study. O.M.A. and R.E. assisted with the coordination and
- execution of the study. R.E., M.E.P., C.K. and T.A. coordinated sample collection. M.I.B.,
- I.M.O, D.Y-C., O.M.A. and N.V. performed the diagnostic tests. O.M.A. and N.V. analyzed
- the data. O.M.A. assisted with the design of the statistical analysis. O.M.A., N.V., and
- A.L.W. wrote and edited the manuscript.
- 255

256 Acknowledgements

- 257 We thank the study participants for their time and cooperation. This work was funded by
- Tempus Labs, Inc (A.L.W), Yale Center for Clinical Investigation TL1 TR001864 (M.E.P.)
- and Fast Grant from Emergent Ventures at the Mercatus Center at George Mason
- 260 University (A.L.W).

It is made available under a CC-BY-NC-ND 4.0 International license .

References 261

- CDC: Interim Laboratory Biosafety Guidelines for Handling and Processing 262 1. 263 Specimens Associated with Coronavirus Disease 2019 (COVID-19). https://www.cdc.gov/coronavirus/2019-ncov/lab/lab-biosafety-guidelines.html.
- 264
- Last Accessed 2021/11/30. 265
- 266 2. Patterson EI, Prince T, Anderson ER, Casas-Sanchez A, Smith SL, Cansado-
- Utrilla C, Solomon T, Griffiths MJ, Acosta-Serrano Á, Turtle L, Hughes GL: 267
- Methods of Inactivation of SARS-CoV-2 for Downstream Biological Assays. J 268 Infect Dis 2020, 222:1462-1467. 269
- 270 3. Darnell MER, Subbarao K, Feinstone SM, Taylor DR: Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J Virol 271 272 Methods 2004, 121:85-91.
- Pagat A-M, Seux-Goepfert R, Lutsch C, Lecouturier V, Saluzzo J-F, Kusters IC: 273 4.
- 274 Evaluation of SARS-Coronavirus Decontamination Procedures. Appl Biosaf 2007,
- 275 12:100-108.
- 276 5. Kampf G, Voss A, Scheithauer S: Inactivation of coronaviruses by heat. J Hosp 277 Infect 2020, 105:348-349.
- Leclercg I, Batéjat C, Burguière AM, Manuguerra J-C: Heat inactivation of the 278 6. 279 Middle East respiratory syndrome coronavirus. Influenza Other Respi Viruses 280 2014, 8:585-586.
- 281 7. Batéjat C, Grassin Q, Manuguerra J-C, Leclercg I: Heat inactivation of the severe 282 acute respiratory syndrome coronavirus 2. J Biosaf Biosecur 2021, 3:1-3.

It is made available under a CC-BY-NC-ND 4.0 International license .

- Smyrlaki I, Ekman M, Lentini A, Rufino de Sousa N, Papanicolaou N, Vondracek
 M, Aarum J, Safari H, Muradrasoli S, Rothfuchs AG, Albert J, Högberg B, Reinius
 B: Massive and rapid COVID-19 testing is feasible by extraction-free SARS-CoV 2 RT-PCR. Nat Commun 2020, 11:4812.
- 287 9. Wyllie AL, Fournier J, Casanovas-Massana A, Campbell M, Tokuyama M,
- Vijayakumar P, Warren JL, Geng B, Muenker MC, Moore AJ, Vogels CBF, Petrone
- 289 ME, Ott IM, Lu P, Venkataraman A, Lu-Culligan A, Klein J, Earnest R, Simonov M,
- 290 Datta R, Handoko R, Naushad N, Sewanan LR, Valdez J, White EB, Lapidus S,
- 291 Kalinich CC, Jiang X, Kim DJ, Kudo E, Linehan M, Mao T, Moriyama M, Oh JE,
- 292 Park A, Silva J, Song E, Takahashi T, Taura M, Weizman O-E, Wong P, Yang Y,
- Bermejo S, Odio CD, Omer SB, Dela Cruz CS, Farhadian S, Martinello RA, Iwasaki
- A, Grubaugh ND, Ko AI: Saliva or Nasopharyngeal Swab Specimens for Detection
 of SARS-CoV-2. N Engl J Med 2020, 383:1283-1286.
- Allicock OM, Petrone ME, Yolda-Carr D, Breban M, Walsh H, Watkins AE,
 Rothman JE, Farhadian SF, Grubaugh ND, Wyllie AL: Usability of saliva collection
 devices for SARS-CoV-2 diagnostics. medRxiv 2021.
- Vogels CBF, Watkins AE, Harden CA, Brackney DE, Shafer J, Wang J, Caraballo
 C, Kalinich CC, Ott IM, Fauver JR, Kudo E, Lu P, Venkataraman A, Tokuyama M,
 Moore AJ, Muenker MC, Casanovas-Massana A, Fournier J, Bermejo S, Campbell
 M, Datta R, Nelson A, Yale IRT, Dela Cruz CS, Ko AI, Iwasaki A, Krumholz HM,
 Matheus JD, Hui P, Liu C, Farhadian SF, Sikka R, Wyllie AL, Grubaugh ND:
 SalivaDirect: A simplified and flexible platform to enhance SARS-CoV-2 testing
 capacity. Med (N Y) 2021, 2:263-280.e266.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 306 12. CDC: Research Use Only 2019-Novel Coronavirus (2019-nCoV) Real-time RT-
- 307 PCR Primers and Probes. <u>https://www.cdc.gov/coronavirus/2019-ncov/lab/rt-pcr-</u>
 308 panel-primer-probes.html. Last Accessed 2021/08/09.
- 309 13. FDA: SalivaDirect EUA Summary. https://www.fda.gov/media/141192/. Last
- 310 Accessed 2021/12/21.
- 14. FDA: FDA authorizes first test to aid in detecting a type of herpes virus in newborns
- 312 called cytomegalovirus. <u>https://www.fda.gov/news-events/press-</u>
- 313 <u>announcements/fda-authorizes-first-test-aid-detecting-type-herpes-virus-</u>
- 314 <u>newborns-called-cytomegalovirus</u>. Last Accessed 2021/12/21.
- 15. Hanson KE, Barker AP, Hillyard DR, Gilmore N, Barrett JW, Orlandi RR, Shakir
- 316 SM: Self-Collected Anterior Nasal and Saliva Specimens versus Health Care 317 Worker-Collected Nasopharyngeal Swabs for the Molecular Detection of SARS-318 CoV-2. J Clin Microbiol 2020, 58.
- 16. Byrne RL, Kay GA, Kontogianni K, Aljayyoussi G, Brown L, Collins AM, Cuevas
- 320 LE, Ferreira DM, Fraser AJ, Garrod G, Hill H, Hughes GL, Menzies S, Mitsi E,
- 321 Owen SI, Patterson EI, Williams CT, Hyder-Wright A, Adams ER, Cubas-Atienzar
- 322 AI: Saliva Alternative to Upper Respiratory Swabs for SARS-CoV-2 Diagnosis.
- 323 Emerg Infect Dis 2020, 26:2770-2771.
- 17. Sahajpal NS, Mondal AK, Ananth S, Njau A, Ahluwalia P, Newnam G, Lozoya-
- 325 Colinas A, Hud NV, Kota V, Ross TM, Reid MD, Fulzele S, Chaubey A, Hegde M,
- 326 Rojiani AM, Kolhe R: SalivaSTAT: Direct-PCR and Pooling of Saliva Samples
- 327 Collected in Healthcare and Community Setting for SARS-CoV-2 Mass
 328 Surveillance. Diagnostics (Basel) 2021, 11.

It is made available under a CC-BY-NC-ND 4.0 International license .

- 329 18. Gröner A, Broumis C, Fang R, Nowak T, Popp B, Schäfer W, Roth NJ: Effective
 330 inactivation of a wide range of viruses by pasteurization. Transfusion 2018, 58:41331 51.
- Burton J, Love H, Richards K, Burton C, Summers S, Pitman J, Easterbrook L,
 Davies K, Spencer P, Killip M, Cane P, Bruce C, Roberts ADG: The effect of heattreatment on SARS-CoV-2 viability and detection. J Virol Methods 2021,
 290:114087.
- Ott IM, Strine MS, Watkins AE, Boot M, Kalinich CC, Harden CA, Vogels CBF,
 Casanovas-Massana A, Moore AJ, Muenker MC, Nakahata M, Tokuyama M,
 Nelson A, Fournier J, Bermejo S, Campbell M, Datta R, Dela Cruz CS, Farhadian
 SF, Ko AI, Iwasaki A, Grubaugh ND, Wilen CB, Wyllie AL, Yale IRt: Stability of
 SARS-CoV-2 RNA in Nonsupplemented Saliva. Emerg Infect Dis 2021, 27:11461150.
- Espy MJ, Patel R, Paya CV, Smith TF: Comparison of three methods for extraction
 of viral nucleic acids from blood cultures. J Clin Microbiol 1995, 33:41-44.
- Sung H, Yong D, Ki C-S, Kim J-S, Seong M-W, Lee H, Kim M-N: Comparative
 evaluation of three homogenization methods for isolating Middle East respiratory
 syndrome coronavirus nucleic acids from sputum samples for real-time reverse
 transcription PCR. Ann Lab Med 2016, 36:457-462.
- Azmi I, Faizan MI, Kumar R, Raj Yadav S, Chaudhary N, Kumar Singh D, Butola
 R, Ganotra A, Datt Joshi G, Deep Jhingan G, Iqbal J, Joshi MC, Ahmad T: A SalivaBased RNA Extraction-Free Workflow Integrated With Cas13a for SARS-CoV-2
 Detection. Front Cell Infect Microbiol 2021, 11:632646.

It is made available under a CC-BY-NC-ND 4.0 International license .

352	24.	Mahmoud SA, Ganesan S, Ibrahim E, Thakre B, Teddy JG, Raheja P, Abbas WZ:
353		Evaluation of RNA Extraction-Free Method for Detection of SARS-CoV-2 in
354		Salivary Samples for Mass Screening for COVID-19. Biomed Res Int 2021, 2021.
355	25.	de Oliveira CM, Brochi L, Scarpelli LC, Lopes ACW, Levi JE: SARS-CoV-2 saliva
356		testing is a useful tool for Covid-19 diagnosis. J Virol Methods 2021:114241.
357	26.	Genoud V, Stortz M, Waisman A, Berardino BG, Verneri P, Dansey V, Salvatori M,
358		Remes Lenicov F, Levi V: Extraction-free protocol combining proteinase K and
359		heat inactivation for detection of SARS-CoV-2 by RT-qPCR. PLoS One 2021,
360		16:e0247792.
261		

361

It is made available under a CC-BY-NC-ND 4.0 International license .

362 Tables

- 363 Table 1. The number of replicates of spiked saliva samples which were considered positive
- 364 following testing in the alternative workflows including heat pre-treatment with or without
- 365 treatment with proteinase K (PK).

Concentration of spiked	65°C for 15 minutes		95°C for 5 minutes		95°C for 30 minutes	
saliva (virus RNA copies/µL)	With PK	Without PK	With PK	Without PK	With PK	Without PK
6 copies/µL	20/20*	20/20	20/20	20/20	20/20	20/20
3 copies/µL	17/20	20/20	19/20	19/20	12/20	15/20
1.5 copies/µL	15/20	17/20	10/20	15/20	8/20	14/20

366 *Concentrations where at least 19/20 replicates tested positive (indicating the assay limit of detection) are

- shown in bold.
- 368
- 369 Figures

370 Figure 1. Alternative SalivaDirect workflows including heat-pretreatment prior to

371 **sample processing.** In the original SalivaDirect protocol, (A) raw saliva is combined with

372 proteinase K then followed by heat-inactivation of the proteinase K and testing in RT-

373 qPCR. The alternate workflows include an initial heat treatment step (65°C for 15 minutes,

374 95°C for 5 minutes or 95°C for 30 minutes), followed by either (B) testing by RT-qPCR

directly or (C) the addition and inactivation of proteinase K prior to testing by RT-qPCR.

376 (Figure created with BioRender.com)

377

Figure 2. Comparison of the sensitivity of the 6 alternate workflows of the SalivaDirect RT-qPCR saliva-based assay for SARS-CoV-2 detection. Each alternative workflow was evaluated by processing spiked positive saliva at (A) 6, (B) 3,

It is made available under a CC-BY-NC-ND 4.0 International license .

and (C) 1.5 copies/ μ L in 20 replicates, and comparing the CT values as a proxy for workflow sensitivity. Solid lines indicate the median Ct values targeting the N1 gene. The dashed line indicates the detection limit at 40 Ct with samples falling below the dashed line considered negative for SARS-CoV-2.The differences between each of the workflows and the original SalivaDirect protocol were compared by a Wilcoxon test test (p < 0.05, * = 0.03, ** = 0.001). Data used to make this figure can be found in **Table S1**. *Abbreviations: Ct, cycle threshold; ND, not detected; PK, proteinase K.*

388

Figure 3. Detection of SARS-CoV-2 RNA in positive clinical saliva samples across 389 390 the 7 different workflows. Clinical saliva samples positive for SARS-CoV-2 were used 391 to compare the sensitivities in detection across the 7 workflows. (A) Ct values for each of 392 the 20 clinical samples processed with the different workflows. The solid lines indicate the median Ct values and 95% CI for each sample across the different workflows. Each dot 393 394 represents an individual replicate of each of the 20 clinical samples as indicated by the dash on the x-axis. (B) We evaluated the effect of proteinase K on the sensitivity of 395 detection between each of 3 different heat treatment conditions by a Wilcoxon test (p < p396 397 0.05). Matched clinical samples are represented by the solid black line between those processed without proteinase K (blue dots), and those with proteinase K (green dots). 398 The area below the dotted line indicates the detection threshold for the N1 gene. Data 399 used to make this figure can be found in Table S2. (*, p = 0.027; **, p = 0.009) 400 Abbreviations: Ct, cycle threshold; ND, not detected; PK, proteinase K. 401





